Compare KLAC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLAC | NVO |
|---|---|---|
| Founded | 1975 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.5B | 212.7B |
| IPO Year | N/A | N/A |
| Metric | KLAC | NVO |
|---|---|---|
| Price | $1,575.57 | $62.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 10 |
| Target Price | ★ $1,311.64 | $54.25 |
| AVG Volume (30 Days) | 908.5K | ★ 19.2M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | 0.49% | ★ 2.15% |
| EPS Growth | ★ 45.59 | 10.06 |
| EPS | ★ 31.83 | 3.67 |
| Revenue | $12,524,317,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $10.02 | $7.25 |
| Revenue Next Year | $13.71 | $0.24 |
| P/E Ratio | $48.53 | ★ $15.58 |
| Revenue Growth | ★ 22.11 | 16.64 |
| 52 Week Low | $551.33 | $43.08 |
| 52 Week High | $1,571.49 | $93.80 |
| Indicator | KLAC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 76.41 | 72.64 |
| Support Level | $1,396.10 | $56.29 |
| Resistance Level | $1,469.86 | $60.63 |
| Average True Range (ATR) | 42.26 | 1.44 |
| MACD | 22.89 | 0.59 |
| Stochastic Oscillator | 97.55 | 96.28 |
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.